NeoGenomics, Inc. (NASDAQ:NEO) Stock Has Consensus Price Target of $20.88 According to Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $20.88.

Several equities research analysts have recently weighed in on NEO shares. Needham & Company LLC upped their price objective on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, October 6th. Craig Hallum restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Wednesday, July 29th. Piper Sandler reaffirmed an “overweight” rating on shares of NeoGenomics in a research note on Wednesday, October 7th. Wall Street Zen cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $21.00 price objective on shares of NeoGenomics in a research note on Thursday.

NeoGenomics News Summary

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q3 results exceeded expectations. NeoGenomics reported third-quarter revenue of approximately $209 million, up 11.3% year over year, while earnings per share of $0.07 topped the $0.06 consensus estimate. NeoGenomics third-quarter earnings results
• Positive Sentiment: Management raised its full-year outlook. The company increased 2026 revenue guidance to $807 million-$809 million, signaling continued demand for its cancer-testing and laboratory-services business. The improved outlook was highlighted alongside the earnings beat. NeoGenomics raises 2026 guidance
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial upside from recent trading levels. Investors also continue to assess whether the earnings beat and higher guidance leave the stock attractively valued. BTIG Research rating
• Neutral Sentiment: CEO transition planned for January 2027. NeoGenomics disclosed that its chief executive transition is expected early next year. The change could eventually support new strategic initiatives, but investors may initially seek more clarity on succession and execution. NeoGenomics 2026 third-quarter earnings presentation
• Negative Sentiment: Profitability remains a concern. Although adjusted quarterly earnings beat estimates, the company continues to face pressure from weak reported profitability, with a negative net margin and analysts expecting a full-year loss. This may be limiting the stock’s reaction to the stronger revenue outlook.

NeoGenomics Price Performance

NASDAQ:NEO opened at $17.38 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.35 and a current ratio of 3.53. The company has a 50-day moving average of $17.68 and a 200-day moving average of $12.82. NeoGenomics has a 52 week low of $7.07 and a 52 week high of $20.15. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -69.52 and a beta of 1.79.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $209.25 million for the quarter, compared to analysts’ expectations of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 earnings per share. As a group, equities research analysts anticipate that NeoGenomics will post -0.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeoGenomics

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of NeoGenomics by 30.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,782 shares of the medical research company’s stock worth $51,000 after buying an additional 644 shares during the last quarter. Farther Finance Advisors LLC grew its stake in NeoGenomics by 117.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,701 shares of the medical research company’s stock valued at $31,000 after buying an additional 917 shares during the last quarter. Root Financial Partners LLC acquired a new position in NeoGenomics in the 3rd quarter valued at about $29,000. Allworth Financial LP raised its holdings in NeoGenomics by 110.4% in the 2nd quarter. Allworth Financial LP now owns 4,132 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 2,168 shares during the period. Finally, Pictet Asset Management Holding SA raised its holdings in NeoGenomics by 24.1% in the 1st quarter. Pictet Asset Management Holding SA now owns 21,923 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 4,252 shares during the period. Institutional investors own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.